Patient-Oriented Evidence That Matters
FIT Has Similar Yield as Colonoscopy for Colorectal Cancer and Advanced Adenoma Over 10 Years
Am Fam Physician. 2019 May 15;99(10):online.
What is the yield of a screening program based on fecal immunochemical testing (FIT) every two years for 10 years?
Over a 10-year period, the rates of detection of colorectal cancer (CRC) and advanced adenomas using FIT are similar to those seen in studies of screening colonoscopy. This does not prove that FIT reduces morbidity and mortality due to CRC as effectively as colonoscopy. Modeling concludes that a FIT-based screening program will result in half as many colonoscopies as a program based on colonoscopy, a significant reduction in cost, burden, and harm of screening. (Level of Evidence = 2b)
The two most widely recommended strategies for CRC screening are FIT and colonoscopy. Several trials are currently underway to compare these approaches, with cancer-specific mortality as the primary outcome. Until then, we have to rely on observational studies and modeling to understand the benefit of each approach. Although colonoscopy is more sensitive than FIT, especially for the detection of advanced adenomas, what matters is the performance over a long-term screening program, not one-time accuracy. This study reports the results of five rounds of biennial FIT in a screening population 50 to 69 years of age in the Veneto region of northern Italy. The rate of detection of CRC was the highest in the first round of screening when prevalent lesions were detected (3.3 per 1,000 people), declining in subsequent rounds and stabilizing after the third round (approximately 1 per 1,000 people). Between rounds three and six, the CRC detection rate declined slightly from 0.95 to 0.84 per 1,000 people. A similar pattern was seen for advanced adenomas, declining from 15.9 per 1,000 people to approximately 10 per 1,000 people in subsequent rounds. Over the 10-year study period, the cumulative rate of positive FIT results was 25% for men and 17.6% for women. The cumulative rate for advanced adenoma was 60 per 1,000 people, and for CRC was 8.5 per 1,000
Editor's Note: Dr. Ebell is Deputy Editor for Evidence-Based Medicine for AFP and cofounder and Editor-in-Chief of Essential Evidence Plus.
POEMs (patient-oriented evidence that matters) are provided by EssentialEvidence Plus, a point-of-care clinical decision support system published by Wiley-Blackwell. For more information, please see http://www.essentialevidenceplus.com. Copyright Wiley-Blackwell. Used with permission.
For definitions of levels of evidence used in POEMs, see https://www.essentialevidenceplus.com/product/ebm_loe.cfm?show=oxford.
To subscribe to a free podcast of these and other POEMs that appear in AFP, search in iTunes for “POEM of the Week” or go to http://goo.gl/3niWXb.
This series is coordinated by Sumi Sexton, MD, Editor-in-Chief.
A collection of POEMs published in AFP is available at https://www.aafp.org/afp/poems.
Want to use this article elsewhere? Get Permissions